azd4635
Small moleculeexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 17, 2016 (NCT02740985)
Timeline
Indications
Mechanism of action
- Alpha-2b adrenergic receptorANTAGONIST
ADRA2B antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd4635
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04495179 | Phase 2 | Aug 4, 2020 | AstraZeneca, Harvard University, Parexel |
| NCT04478513 | Phase 1 | Jul 21, 2020 | AstraZeneca, Parexel |
| NCT04089553 | Phase 2 | Aug 29, 2019 | AstraZeneca, Columbia University |
| NCT03980821 | Phase 1 | Jun 18, 2019 | AstraZeneca |
| NCT03710434 | Phase 1 | Nov 1, 2018 | AstraZeneca, Quotient |
| NCT03381274 | Phase 1/Phase 2 (Phase 2) | May 8, 2018 | MedImmune |
| NCT02740985 | Phase 1 | Jun 17, 2016 | AstraZeneca, SCRI Development Innovations |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2016 |
| Parexel | For profit | 2 | 0 | 2 | 2020 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| MedImmune | For profit | 1 | 1 | 1 | 2018 |
| Quotient | For profit | 1 | 0 | 1 | 2018 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1